

# Full-year 2021 *results*

sanofi



• Our performance in 2021 was impressive, across the business and in our scientific results. We are poised for success ahead •

*Paul Hudson*  
Chief Executive Officer, Sanofi

## Company sales and business EPS\*

**€37,761m**  
+7.1% (+4.8%)

Full-year 2021  
company sales\*\*



**€6.56**  
+15.5% (+11.9%)

Full-year 2021  
business EPS\*\*

\* Earnings per share  
\*\* Growth rates are expressed at constant exchange rates (CER).  
Growth rates in parentheses are expressed on a reported basis.

## Sales by global business unit



**€12,752m**  
Specialty Care



**€14,218m**  
General Medicines



**€6,323m**  
Vaccines



**€4,468m**  
Consumer Healthcare

## Sales by geography

US  
**€14,385m**

Europe  
**€9,759m**



Rest of  
the World  
**€13,617m**

## R&D transformation



**7**  
positive  
pivotal study  
readouts



**8**  
major product  
approvals  
in the US  
and Europe



**10**  
new molecules  
entering  
the clinical pipeline  
from in-house  
research

For further information on full-year 2021 results and definitions of financial indicators, please refer to the press release issued on February 4, 2022 at:  
[www.sanofi.com/en/investors](http://www.sanofi.com/en/investors)

sanofi



@Sanofi



@Sanofi



@Sanofi



@sanofiaventisTVen